Determination of Plasma Amino Acid Biomarkers by High Performance Liquid Chromatography for Diagnosis of Type 2 Diabetes Mellitus

2013 ◽  
Vol 46 (18) ◽  
pp. 2813-2827 ◽  
Author(s):  
Xiaofei Han ◽  
Hongbin Xiao ◽  
Qingping Liu ◽  
Liangxiao Zhang ◽  
Qianxu Yang ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
High Performance Liquid Chromatography ◽  
Liquid Chromatography ◽  
Amino Acid ◽  
High Performance ◽  
Plasma Amino Acid

A Systematic Review of Analytical Profiles of SGLT2 Inhibitors and their Combinations for Treatment of Type 2 Diabetes Mellitus

2019 ◽  
Vol 15 (7) ◽  
pp. 681-693 ◽  
Author(s):  
Niyatee Savaikar Thakor ◽  
Sunil Vishvanath Amrutkar
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Liquid Chromatography ◽  
High Performance ◽  
The United States ◽  
Sglt2 Inhibitors ◽  
Fixed Dose ◽  
Layer Chromatography

The frequency of Type 2 Diabetes Mellitus worldwide is rising rapidly and is estimated to reach 4.4% of the world’s population or about 366 million people by 2030. In the view of National Diabetes Statistics report 2017, 30.3 million people have diabetes in the United States (9.4%) of total population, out of which, 23.1 million are diagnosed and 7.2 million (23.8%) people with Diabetes are undiagnosed. One of the recently introduced therapeutic classes is Sodium Glucose co- Transporter 2 (SGLT2) Inhibitors. Since 2010 USFDA has approved 6 single dose and 7 fixed dose combinations for treatment of Type 2 Diabetes Mellitus. SGLT2 Inhibitors such as Canagliflozin, Dapagliflozin and Empagliflozin are in combinations with most of the dosage forms. This article reviews published analytical methods reported so far in the literature to find SGLT2 inhibitors. They include various techniques like spectrophotometry, high-performance liquid chromatography, liquid chromatography-electrospray ionization-tandem mass spectrometry and high-performance thin layer chromatography for their routine, impurity profiling and stability indicating determination in different pharmaceutical matrices.

SUMMARY OF CHROMATOGRAPHIC ANALYSIS METHODS OF ANTI DIABETIC GLIFLOZINS EMPAGLIFLOZIN, CANAGLIFLOZIN AND DAPAGLIFLOZIN

INDIAN DRUGS ◽  
2019 ◽  
Vol 56 (07) ◽  
pp. 80-83
Author(s):  
W. A Zaghary ◽  
S. Mowaka ◽  
M. S. Hendy ◽  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Biological Samples ◽  
Chromatographic Analysis ◽  
Dosage Forms ◽  
Drug Control ◽  
Bioanalytical Assays

Sodium glucose co-transporter-2 (SGLT-2) inhibitors are relatively new developed effective oral anti-diabetic agents used in treatment of type 2 Diabetes Mellitus. They present either alone or in combination with other ant diabetic agents such as linagliptin, Saxagliptin and metformin. Therefore, the necessity to explore and compare the existing analytical and bioanalytical assays used for determination of such drugs either single or in combination is crucial. Many methods were reported in the literature for the bio-analysis and analysis of three novel gliflozins with applying the method on different dosage forms and different chemical and biological samples. Furthermore, this review offered an overview of different methods used for determination of every drug alone in a tabulated comparative way. Moreover, the present review emphasized the most common stability indicating assays to be of interest to the analysts in the area of drug control.

“CHANGES IN THE NERVOUS SYSTEM IN PATIENTS WITH DIABETES MELLITUS TYPE 2 WITH NEPHROPATHY AND PROGNOSTIC SIGNIFICANCE OF NEUROMARKERS OF BRAIN INJURY. LITERATURE REVIEW"

2021 ◽  
pp. 3-8
Author(s):  
Yu. Urmanova ◽  
A. Holikov
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Nervous System ◽  
Type 2 Diabetes Mellitus ◽  
Biochemical Markers ◽  
Prognostic Significance ◽  
Functional Changes ◽  
Neurospecific Proteins

THE PURPOSE OF THE STUDY is to carry out an analysis of the literature evaluating diabetic encephalopathy by determining neuromarkers. MATERIAL AND METHODS. In this article, the authors analyzed the literature on the role of neuromarkers in patients with type 2 diabetes mellitus undergoing program hemodialysis. RESEARCH RESULTS. Among biochemical markers, the determination of the level of neurospecific proteins is actively being investigated. The main part of them is autoantigens, entering the bloodstream, can cause the appearance of autoantibodies, which, when the blood-brain barrier is impaired, enter the brain from the blood vessel and cause morphological changes, destructive processes in neurons, as well as the development of nonspecific acute-phase reactions like edema or inflammation. Biomarker studies for the diagnosis of various brain lesions have been under way for more than 20 years, but at present no ideal biomarker has been found. Among biochemical markers, the determination of the level of neurospecific proteins is being actively studied. In patients with type 2 diabetes mellitus undergoing hemodialysis, this issue is also relevant in view of the frequent vascular cerebrovascular complications, but few studies have been conducted. CONCLUSIONS. All of the above emphasizes the need to identify the features of clinical and functional changes in the nervous system in patients with type 2 diabetes mellitus receiving program hemodialysis and to evaluate the prognostic value of neuromarkers in early detection of the degree of brain damage. 

N-glycosylation profiling of Type 2 diabetes mellitus from baseline to follow-up: an observational study in a Ghanaian population

2021 ◽  
Author(s):  
Eric Adua ◽  
Elham Memarian ◽  
Ebenezer Afrifa-Yamoah ◽  
Alyce Russell ◽  
Irena Trbojević-Akmačić ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Liquid Chromatography ◽  
Ultra Performance Liquid Chromatography ◽  
Coefficients Of Variation ◽  
Individual Variations ◽  
Glycan Profiling

Aim: The study sought to determine the patterns of N-glycan profiles among Type 2 diabetes mellitus (T2DM) patients over a 6-month period. Materials & methods: Biochemical and clinical data were obtained from 253 T2DM patients at baseline and follow-up. Ultra-performance liquid chromatography and statistical methods were applied for N-glycan profiling. Results: The coefficients of variation were 28% and 29% at baseline and follow-up, respectively, whereas the range of N-glycan variability was from 11% to 56%. Apart from GP1 (FA2) and GP29 (FA3G3S [3,3,3]3), the intra-individual variations of N-glycan peaks were not statistically significant. Conclusion: N-glycan profiles were stable over 6-month period in T2DM patients and could be used to monitor biochemical changes in relation with T2DM comorbidities.

Sign in / Sign up

Export Citation Format

Share Document